Immunovia AB (IMMNOV) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Immunovia Q2 Interim Report 2025 conference call. I am Moira, the Chorus Call Operator. I would like to remind you that all participants will be in listen-only mode and the conference has been recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Jeff Borcharding, CEO. Please go ahead. Welcome to the Q2 2025 interim report for Immunovia. Thanks very much for joining us. I am Jeff Borcharding, the CEO of Immunovia, and today I'm also joined by Adam Beckstrom of ProRata. We engaged ProRata earlier this year to manage accounting, financial reporting, and provide CFO advisory services to Immunovia. Adam and his team provide deep expertise, and they have been terrific partners, providing us with excellent services at a much lower cost to the company compared to when we were employing a CFO and accounting team. So we're very pleased to be working with Adam and the ProRata team and excited to have him joining us today. Thank you. Yes. We've spoken often about Immunovia's mission. This mission drives the work that we do every day to increase pancreatic cancer survival through early detection in high-risk individuals. Today's call is especially important as we think about this mission because we've never been closer to achieving that mission. We are taking a significant step forward as we progress through this journey to making an impact in pancreatic cancer. The launch of the Pancreature Test next week is a key milestone in this journey, and we're excited to share information about that ...